Developing exposure/response models for anticancer drug treatment: special considerations
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
[PDF][PDF] Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould, AC Walz, T Lave, JP Gibbs, B Frame - cyberleninka.org
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
[HTML][HTML] Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.
DR Mould, AC Walz, T Lave, JP Gibbs… - CPT: Pharmacometrics …, 2015 - europepmc.org
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould, AC Walz, T Lave, JP Gibbs… - CPT: Pharmacometrics …, 2015 - search.proquest.com
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould, AC Walz, T Lave… - CPT …, 2015 - pubmed.ncbi.nlm.nih.gov
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
[PDF][PDF] Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould, AC Walz, T Lave, JP Gibbs, B Frame - researchgate.net
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
[HTML][HTML] Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould, AC Walz, T Lave, JP Gibbs… - CPT: Pharmacometrics …, 2015 - ncbi.nlm.nih.gov
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
[引用][C] Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
DR Mould - CPT: pharmacometrics & systems pharmacology, 2015 - cir.nii.ac.jp
Developing Exposure/Response Models for Anticancer Drug Treatment: Special
Considerations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Considerations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.
DR Mould, AC Walz, T Lave, JP Gibbs… - CPT: Pharmacometrics …, 2015 - europepmc.org
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …